Next Article in Journal
The links between learning load and well-being of high school seniors
Previous Article in Journal
Changes in the prevalence of metabolic syndrome and smoking habits during a 10-year period and relation between these risk factors and ischemic heart disease among men aged 45–64 years
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Open AccessArticle

A new approach to the treatment of dyslipidemia

Department of Cardiology, Kaunas University of Medicine, Lithuania
*
Author to whom correspondence should be addressed.
Medicina 2008, 44(5), 407; https://doi.org/10.3390/medicina44050053
Received: 28 January 2008 / Accepted: 9 May 2008 / Published: 14 May 2008
During the last decade, the evidence of beneficial effects of cholesterol lowering in patients with coronary heart disease has been proven in many clinical trials. The National Cholesterol Education Program (NCEP) released 2004 update to the Adult Treatment Panel III (ATP III) guidelines. The new guidelines of European Society of Cardiology announced in 2007 support more intensive LDL-C lowering in patients at high risk of cardiovascular diseases. For patients at the highest risk of cardiovascular diseases (diabetic patients with coronary heart disease), the recommended LDL-C goal is <1.8 mmol/L. In very high-, high-, and moderately high-risk patients, statin therapy should be considered with a treatment targeting an LDL-C reduction of 30– 40%. Clinical studies have shown that statin therapy alone is not always effective, especially in patients with primary hypercholesterolemia. Furthermore, high doses of statins can increase the possibility of adverse events. The combination of statins with intestinal cholesterol absorption inhibitors is more effective than statin monotherapy in LDL-C lowering and is well tolerated.
Keywords: low-density lipoprotein cholesterol (LDL-C); statins; cholesterol absorption inhibitors low-density lipoprotein cholesterol (LDL-C); statins; cholesterol absorption inhibitors
MDPI and ACS Style

Kėvelaitienė, S.; Šlapikas, R. A new approach to the treatment of dyslipidemia. Medicina 2008, 44, 407.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop